Drug-class specific impact of antivirals on the reproductive capacity of HIV
about
HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirsHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisExplaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug actionEstimating HIV-1 fitness characteristics from cross-sectional genotype dataOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsA comparison of elasticities of viral levels to specific immune response mechanisms in human immunodeficiency virus infection.Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Dynamics of an HIV Model with Multiple Infection Stages and Treatment with Different Drug Classes.Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration.Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes.Insight into treatment of HIV infection from viral dynamics modelsModelling the Drugs Therapy for HIV Infection with Discrete-Time Delay
P2860
Q28477500-F64BF69C-9F53-4FFF-81B1-A67BF133CB13Q28478993-B4E0BE18-47AA-47CF-A02D-BC8F79668506Q28481276-9BD64E7A-EA5A-4F68-9BE6-BAA7689DDD8DQ28486262-D5060F4E-C8D2-4DA2-A5C8-81A33F4C2379Q28489076-11521362-F348-452E-8037-0543BEFACD3EQ28544753-12709DA7-2D7A-4405-A988-677704A2F8D3Q28547109-0480D1AB-5D67-4691-A910-B9C99B0B0D19Q30596957-B77B05DE-4226-423D-8903-71FA6FBEEBEFQ35598505-0C2DDF01-4FEB-4434-B06E-1B759454EC9DQ37126494-66F6A70B-4B16-4997-AEAB-2D59E1BB765DQ40026816-FDA44E4F-2C6C-469E-BA67-A200D52C1D63Q40134547-318F80E8-7B84-47C2-8588-A2A95C7B99B5Q55299659-8E420627-4810-49B3-9A07-2E9D867AF42CQ58788145-4DAD4595-5CB0-47E3-9729-D5133C9BEBCAQ59037779-EC8D3C0F-1B2E-49DE-BAB2-A39D02795276
P2860
Drug-class specific impact of antivirals on the reproductive capacity of HIV
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@ast
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@en
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@nl
type
label
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@ast
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@en
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@nl
prefLabel
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@ast
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@en
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@nl
P2860
P3181
P1476
Drug-class specific impact of antivirals on the reproductive capacity of HIV
@en
P2093
Stephan Menz
Wilhelm Huisinga
P2860
P304
P3181
P356
10.1371/JOURNAL.PCBI.1000720
P407
P577
2010-03-26T00:00:00Z